Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The leading Oxford’s chimpanzee adenovirus vaccine platform has been engineered as a Zika vaccine, opening the door to clinical trials at the University of Oxford and Mexico. The development was published in Nature Communications in a multinational team effort lead by Prof. Arturo Reyes-Sandoval, the Jenner Institute (NDM) in collaboration with Imperial College London, University of Glasgow, Harvard Medical School, and the Oswaldo Cruz Foundation in Brazil. 

Read full article

Similar stories

Therapeutic HIV vaccine with Oxford technology achieves encouraging results

A phase I/IIa clinical trial that the University of Oxford collaborated on has demonstrated that a T-cell therapeutic HIV vaccine was associated with better control of the virus rebound when antiretroviral therapy (ART) was temporarily withdrawn.

Oxford vaccine saved most lives in its first year of rollout

When the University of Oxford developed a vaccine that was effective against COVID-19, ensuring that it could be rolled out globally and in perpetuity for low- and middle-income countries was of paramount importance.

Oxford scientist named Australian of the Year in the UK

The Oxford Vaccine Group’s Lead Statistician, Professor Merryn Voysey, received the prestigious Australian of the Year in the UK award at a gala dinner recently.

Oxford team to begin novel coronavirus vaccine research

A research team at Oxford University’s Jenner Institute is preparing to begin clinical testing of a novel coronavirus vaccine candidate.

New MERS vaccine clinical trial starts in Saudi Arabia

The King Abdullah International Medical Research Centre (KAIMRC), in collaboration with the University of Oxford’s Jenner Institute has started a Phase I clinical trial in the Kingdom of Saudi Arabia (KSA) for a vaccine against Middle East Respiratory Syndrome Coronavirus (MERS-CoV).